IRAK-M Antibody
| Code | Size | Price |
|---|
| PSI-2355-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-2355-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
IRAK-M Antibody: ASRT5, IRAKM, Interleukin-1 receptor-associated kinase 3, IL-1 receptor-associated kinase M, IRAK-3
Application Note:
IRAK-M antibody can be used for detection of IRAK-M by Western blot at 1 μg/mL. IRAK-M antibody can also detect IRAK-M by immunohistochemistry at 2 μg/mL. For immunofluorescence start at 10 μg/mL.
Antibody validated: Western Blot in mouse and rat samples; Immunohistochemistry in human and rat samples and Immunofluorescence in mouse and rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse and rat samples; Immunohistochemistry in human and rat samples and Immunofluorescence in mouse and rat samples. All other applications and species not yet tested.
Background:
IRAK-M Antibody: Interleukin-1 (IL-1) and lipopolysaccharide (LPS) induces cellular response through IL-1 receptor (IL-1R) and Toll like receptors (TLR). IL-1 receptor-associated kinase (IRAK and IRAK2) mediates the activation of NF-betaB by IL-1/Toll receptors, which is a pivotal transcription factor mediating inflammatory and immune response. A novel member in the IRAK/Pelle family was recently identified and designated IRAK-M. IRAKs associate with IL-1/Toll receptors after IL-1 or LPS stimulation and the dominant negative mutants of IRAKs inhibit IL-1 or LPS induced NF-betaB activation. Members in IRAK/Pelle family play a central role in IL-1R/TLR mediated inflammatory responses to cytokine IL-1 and LPS.
Background References:
- Cao Z, Henzel WJ, and Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 1996; 271:1128-31.
- Muzio M, Ni J, Feng P, et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 1997; 278:1612-5.
- Wesche H, Gao X, Li X, et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J. Biol. Chem. 1999; 274:19403-10.
Buffer:
IRAK-M Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
IRAK-M antibody was raised against a peptide corresponding to 16 amino acids near the carboxy terminus of human IRAK-M.
The immunogen is located within the last 50 amino acids of IRAK-M.
The immunogen is located within the last 50 amino acids of IRAK-M.
NCBI Gene ID #:
11213
NCBI Official Name:
interleukin-1 receptor-associated kinase 3
NCBI Official Symbol:
IRAK3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 66 kDa
Observed: 70 kDa
Observed: 70 kDa
Protein Accession #:
NP_009130
Protein GI Number:
5225377
Purification:
IRAK-M Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
SPECIFICITY:
IRAK-M antibody is predicted to have no cross reactivity to other members of the IRAK family.
Swissprot #:
Q9Y616
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | IRAK-M Peptide | PSI-2355P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|